Search Results

Enable Injections, Inc. announced the Company has expanded its partnership with Roche through a collaboration, allowing Roche to develop and apply Enable’s expertise and enFuse delivery technology to specific Roche development programs.

Enable Injections, Inc. and Serina Therapeutics announced a partnership to develop and commercialize SER-252 in combination with enFuse for the treatment of Parkinson’s disease.

Enable Injections, Inc., a company developing and manufacturing the enFuse® platform of wearable drug delivery systems, is pleased to announce the appointment of Vickie Capps to the company’s Board of Directors as the head of the audit committee.

Enable Injections, Inc. (“Enable”) today announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI Injector (enFuse®) for the subcutaneous delivery of EMPAVELI® (pegcetacoplan), which is commercialized in the United States by Apellis Pharmaceuticals, Inc. for adults with paroxysmal nocturnal hemoglobinuria (PNH).

The investigational injection fosgonimeton appeared to have better efficacy in patients with more severe disease, according to post-hoc subgroup analyses, though none resulted in statistically significant effects.

Health Canada authorizes Tecentriq SC (atezolizumab, solution for subcutaneous injection), the first cancer immunotherapy subcutaneous injection, for multiple cancer types.